Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed on First-Line Osimertinib Due to MET-driven Resistance Mechanisms By Ogkologos - August 6, 2025 485 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SAVANNAH study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR 2023 ASCO Annual Meeting Research Round Up: Advances in Treating Gynecologic... August 17, 2023 Improving research with registered reports May 16, 2022 ESMO Immuno-Oncology Congress 2022, 7-9 December, Geneva, Switzerland November 29, 2022 Sofi Leota Was Diagnosed With Breast Cancer At 23. Two Years... July 23, 2020 Load more HOT NEWS Significant iDFS Benefit with Adding Ribociclib to a Nonsteroidal Aromatase Inhibitor... FDA Grants Accelerated Approval to Epcoritamab-bysp for Relapsed or Refractory Follicular... Efficacy and Safety of Trastuzumab and Pertuzumab in Combination with FLOT... Laser-Based Device Detects and Kills Melanoma Cells in the Blood, Study...
